Greg Divis, Avadel Pharmaceuticals CEO
October 17, 2024 11:26 AM EDTUpdated 12:01 PM
Pharma
FDA+

FDA ex­pands la­bel for Avadel's nar­colep­sy drug in­to chil­dren

Katherine Lewin

News Reporter

Avadel Phar­ma­ceu­ti­cals said its once-night­ly nar­colep­sy drug Lum­ryz can now be used to treat chil­dren old­er than 7 years of age.

The Thurs­day

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Benev­o­len­tAI CEO is out af­ter less than a year on the job

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug

First clin­i­cal test of RNA edit­ing re­stores miss­ing pro­tein in ge­net­ic dis­ease, Wave says

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times